WuXi PharmaTech's Novel Anti-IL6 Monoclonal Antibody Advances in Clinical Trials for Rheumatoid Arthritis Treatment

Strategic Insights -

WuXi PharmaTech's (NYSE: WX) partnership with MedImmune has reached a significant milestone as the Investigational New Drug (IND) application for WuXi MedImmune's novel anti-IL6 monoclonal antibody has been accepted for review by the China Food and Drug Administration (CFDA). This novel biologic is intended for the treatment of rheumatoid arthritis, and WuXi AppTec's facilities in Shanghai, Suzhou, and Wuxi have passed the Jiangsu FDA's onsite inspections, ensuring the highest quality standards. WuXi AppTec will continue to provide manufacturing, regulatory, pre-clinical, and clinical trial support for the program.

Key Takeaways:

  • The IND application for WuXi MedImmune's novel anti-IL6 monoclonal antibody has been entered into the system of the CFDA for technical review.
  • WuXi AppTec's biologics and pre-clinical facilities in Shanghai, Suzhou, and Wuxi have passed the Jiangsu FDA's onsite inspections, ensuring cGMP standards compliance.
  • WuXi AppTec will continue to provide manufacturing, regulatory, pre-clinical, and clinical trial support for the program.
  • WuXi PharmaTech's capabilities in integrated biologics discovery, development, and manufacturing offer a global platform with high-quality standards.
  • This initiative showcases WuXi's capabilities as a gateway for developing novel biologics in China.
  • MedImmune is the global biologics research and development arm of AstraZeneca.
  • WuXi AppTec completed all CMC, nonclinical, and clinical sections of the dossier in December 2014.
  • The first joint venture between a global company and a Chinese company to develop novel biologics in China was formed in September 2012.

Statistics:

  • Over 100 million people worldwide suffer from rheumatoid arthritis (Source: Arthritis Foundation).
  • Rheumatoid arthritis is a chronic autoimmune disease that affects the joints and can cause significant pain and disability.
  • WuXi AppTec's facilities in Shanghai, Suzhou, and Wuxi have passed the Jiangsu FDA's onsite inspections (January 2015).
  • WuXi AppTec is the first Chinese company to meet cGMP standards of the United States, the European Union, and China.
  • The WuXi-MedImmune partnership is a significant milestone in the development of novel biologics in China.

Sources:

  • "WuXi PharmaTech (Cayman) Inc. Announces Acceptance of IND Application for WuXi MedImmune's Novel Anti-IL6 Monoclonal Antibody" (NewsRx LLC, 2015).
  • "WuXi AppTec and MedImmune Form Joint Venture to Develop and Commercialize MEDI5117" (WuXi AppTec, 2012).